Direxion Daily MU Bull 2X Shares (NASDAQ: MUU)

Latest news for Direxion Daily MU Bull 2X Shares (NASDAQ:MUU)

Direxion Daily MU Bull 2X Shares

semiconductor

News

Specialty ETFs

Tech

ETFs

AVGO

New leveraged ETFs targeting Broadcom and Micron in the semiconductor industry have been launched by Direxion, providing traders with tools for short-term trading.

Broadcom, Micron Traders Get New Tools With Direxion&#39;s Latest Leveraged Bull And Bear ETFs

MARUBUN CORP by Marubun Corp.

U.S. stocks traded mostly higher this morning, with the Dow Jones index gaining around 100 points on Friday.
Following the market opening Friday, the Dow traded up 0.24% to 42,445.30 while the NASDAQ fell 0.13% to 19,347.54. The S&amp;P 500 also rose, gaining, 0.08% to 5,871.87.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a>
Leading and Lagging Sectors Real estate shares rose by 1.1% on Friday.
In trading on Friday, consumer staples shares fell by 0.4%.
Top Headline
Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) reported better-than-expected earnings for its fourth quarter on Friday.
The company posted quarterly earnings of 14 cents per share which beat the analyst consensus estimate of 8 cents per share. The company reported quarterly sales of $5.938 billion which beat the analyst consensus estimate of $5.932 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>My Size, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYSZ#NASDAQ">MYSZ</a>) shares shot up 349% to $6.11.</li>
<li>Shares of Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>)got a boost, surging 119% to $0.9901.</li>
<li>Taoping Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares were also up, gaining 73% to $0.5490 after the company announced it received an additional 180 calendar days for compliance with the Nasdaq minimum bid price requirement.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares dropped 76% to $0.3895 as the company reported the pricing of $20.0 million follow on offering.</li>
<li>Shares of Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) were down 63% to $0.7600 after the company announced top-line results of its NAVIGATE clinical trial and confirmed belapectin did not achieve statistical significance.</li>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) was down, falling 54% to $5.09.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $68.73 while gold traded up 1.2% at $2,640.30.
Silver traded up 1.2% to $29.775 on Friday, while copper rose 0.4% to $4.0930.
Euro zone
European shares were lower today. The eurozone's STOXX 600 dipped 1.3%, Germany's DAX fell 0.9% and France's CAC 40 declined 0.7%. Spain's IBEX 35 Index fell 0.2%, while London's FTSE 100 fell 0.5%.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei 225 falling 0.29%, Hong Kong's Hang Seng Index falling 0.16%, China's Shanghai Composite Index declining 0.06% and India's BSE Sensex falling 1.49%.
Economics
<ul>
<li>The University of Michigan consumer sentiment rose to 74 in December, recording the highest level since April, and versus a reading of 71.8 in November.</li>
<li>U.S. personal income increased by 0.3% month-over-month in November compared to a revised 0.7% gain in October.</li>
<li>Personal spending increased by 0.4% to an annualized rate of $20.2 trillion in November.</li>
<li>The U.S. personal consumption expenditures price index rose 0.1% month-over-month in November down from 0.2% in each of the prior two months and compared to market estimates of 0.2%.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42616304/top-3-risk-off-stocks-that-may-collapse-this-month">Top 3 Risk Off Stocks That May Collapse This Month</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

GALT

HSDT

MYSZ

PRFX

TAOP

Dow Surges 100 Points, Carnival Earnings Top Views

Goldman Sachs analyst George Tong maintains Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) with a Buy and lowers the price target from $236 to $211.

Price Target

Analyst Ratings

CTAS

Goldman Sachs Maintains Buy on Cintas, Lowers Price Target to $211

Goldman Sachs analyst Ati Modak maintains Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) with a Neutral and raises the price target from $138 to $201.

GTLS

Goldman Sachs Maintains Neutral on Chart Industries, Raises Price Target to $201

Financial giants have made a conspicuous bearish move on Humacyte. Our analysis of options history for Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) revealed 9 unusual trades.
Delving into the details, we found 11% of traders were bullish, while 77% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $370,504, and 4 were calls, valued at $132,840.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $4.0 to $7.5 for Humacyte over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Humacyte's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Humacyte's significant trades, within a strike price range of $4.0 to $7.5, over the past month.
<h3>Humacyte Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734708639_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUMA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.35</td>
<td>$1.3</td>
<td>$1.35</td>
<td>$5.50</td>
<td>$114.5K</td>
<td>21</td>
<td align="right">384</td>
</tr>
<tr>
<td>HUMA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$1.45</td>
<td>$1.4</td>
<td>$1.45</td>
<td>$5.00</td>
<td>$100.0K</td>
<td>4.4K</td>
<td align="right">63</td>
</tr>
<tr>
<td>HUMA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.45</td>
<td>$1.25</td>
<td>$1.45</td>
<td>$5.00</td>
<td>$64.8K</td>
<td>10</td>
<td align="right">512</td>
</tr>
<tr>
<td>HUMA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.7</td>
<td>$0.65</td>
<td>$0.65</td>
<td>$4.50</td>
<td>$57.9K</td>
<td>141</td>
<td align="right">908</td>
</tr>
<tr>
<td>HUMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.25</td>
<td>$2.0</td>
<td>$2.0</td>
<td>$4.00</td>
<td>$40.0K</td>
<td>1.0K</td>
<td align="right">208</td>
</tr>
</tbody>
</table>

<h3>About Humacyte</h3>
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
After a thorough review of the options trading surrounding Humacyte, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Humacyte Standing Right Now?</h3>
<ul>
<li>With a trading volume of 42,801,618, the price of HUMA is up by 66.66%, reaching $5.77.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 91 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Humacyte</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $21.666666666666668.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from D. Boral Capital keeps a Buy rating on Humacyte with a target price of $25. 
&#x2A; An analyst from HC Wainwright &amp; Co. has revised its rating downward to Buy, adjusting the price target to $15. 
&#x2A; An analyst from D. Boral Capital persists with their Buy rating on Humacyte, maintaining a target price of $25. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Humacyte with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

HUMA

Spotlight on Humacyte: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ARM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for ARM Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 18% bullish and 72%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $211,334, and 5 are calls, for a total amount of $268,910.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $220.0 for ARM Holdings during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for ARM Holdings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ARM Holdings's whale activity within a strike price range from $50.0 to $220.0 in the last 30 days. 
<h3>ARM Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734708633_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$21.65</td>
<td>$20.7</td>
<td>$20.7</td>
<td>$150.00</td>
<td>$103.5K</td>
<td>27</td>
<td align="right">51</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$18.5</td>
<td>$18.1</td>
<td>$18.1</td>
<td>$115.00</td>
<td>$65.1K</td>
<td>1.9K</td>
<td align="right">36</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/27/24</td>
<td>$1.95</td>
<td>$1.94</td>
<td>$1.95</td>
<td>$125.00</td>
<td>$48.7K</td>
<td>801</td>
<td align="right">559</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$7.2</td>
<td>$6.95</td>
<td>$6.95</td>
<td>$220.00</td>
<td>$41.7K</td>
<td>164</td>
<td align="right">60</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.51</td>
<td>$1.5</td>
<td>$1.5</td>
<td>$125.00</td>
<td>$37.5K</td>
<td>3.1K</td>
<td align="right">266</td>
</tr>
</tbody>
</table>

<h3>About ARM Holdings</h3>
Arm Holdings is the IP owner and developer of the ARM architecture (ARM stands for Acorn RISC Machine), which is used in 99% of the world's smartphone CPU cores, and it also has high market share in other battery-powered devices like wearables, tablets, or sensors. Arm licenses its architecture for a fee, offering different types of licenses depending on the flexibility the customer needs. Customers like Apple or Qualcomm buy architectural licenses, which allows them to modify the architecture and add or delete instructions to tailor the chips to their specific needs. Other clients directly buy off-the-shelf designs from Arm. Off-the-shelf and architectural customers pay a royalty fee per chip shipped.
Having examined the options trading patterns of ARM Holdings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of ARM Holdings</h3>
<ul>
<li>Trading volume stands at 1,115,831, with ARM's price down by -0.09%, positioned at $131.97.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 47 days.</li>
</ul>
<h3>What The Experts Say On ARM Holdings</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $157.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Wells Fargo downgraded its rating to Overweight, setting a price target of $155. 
&#x2A; In a cautious move, an analyst from UBS downgraded its rating to Buy, setting a price target of $160. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ARM Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On ARM Holdings

Financial giants have made a conspicuous bullish move on Walt Disney. Our analysis of options history for Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) revealed 10 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 20% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $162,899, and 6 were calls, valued at $492,203.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $140.0 for Walt Disney over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Walt Disney's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Walt Disney's significant trades, within a strike price range of $55.0 to $140.0, over the past month.
<h3>Walt Disney Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734708628_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.8</td>
<td>$10.5</td>
<td>$10.85</td>
<td>$110.00</td>
<td>$216.9K</td>
<td>4.2K</td>
<td align="right">218</td>
</tr>
<tr>
<td>DIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.9</td>
<td>$10.55</td>
<td>$10.82</td>
<td>$110.00</td>
<td>$108.1K</td>
<td>4.2K</td>
<td align="right">838</td>
</tr>
<tr>
<td>DIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$57.25</td>
<td>$54.6</td>
<td>$55.78</td>
<td>$55.00</td>
<td>$55.8K</td>
<td>10</td>
<td align="right">10</td>
</tr>
<tr>
<td>DIS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.75</td>
<td>$5.1</td>
<td>$5.3</td>
<td>$115.00</td>
<td>$53.0K</td>
<td>5.7K</td>
<td align="right">100</td>
</tr>
<tr>
<td>DIS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/10/25</td>
<td>$2.0</td>
<td>$1.93</td>
<td>$1.93</td>
<td>$113.00</td>
<td>$52.3K</td>
<td>98</td>
<td align="right">546</td>
</tr>
</tbody>
</table>

<h3>About Walt Disney</h3>
Disney operates in three global business segments: entertainment, sports, and experiences. Entertainment and experiences both benefit from the firm's ownership of iconic franchises and characters. Entertainment includes the ABC broadcast network, several cable television networks, and the Disney+ and Hulu streaming services. Within the segment, Disney also engages in movie and television production and distribution, with content licensed to movie theaters, other content providers, or, increasingly, kept in-house for use on Disney's own streaming platform and television networks. The sports segment houses ESPN and the ESPN+ streaming service. Experiences contains Disney's theme parks and vacation destinations, and also benefits from merchandise licensing.
After a thorough review of the options trading surrounding Walt Disney, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Walt Disney</h3>
<ul>
<li>With a trading volume of 2,968,688, the price of DIS is up by 0.01%, reaching $111.38.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 47 days from now.</li>
</ul>
<h3>What The Experts Say On Walt Disney</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $127.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies has revised its rating downward to Hold, adjusting the price target to $120. 
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Walt Disney, maintaining a target price of $135. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Walt Disney with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Smart Money Is Betting Big In DIS Options

Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) has outperformed the market over the past 5 years by 10.21% on an annualized basis producing an average annual return of 22.93%. Currently, Sea has a market capitalization of $63.07 billion. 
Buying $100 In SE: If an investor had bought $100 of SE stock 5 years ago, it would be worth $282.68 today based on a price of $109.82 for SE at the time of writing.
<h3>Sea's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734708613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Sea Stock In The Last 5 Years

WIIM

Mission Produce shares are trading higher after the company reported better-than-expected Q4 sales results.

Macro Economic Events

Economics

Federal Reserve

Goolsbee Says Rate Path Will Be Determined By Employment, Prices; Wide Consensus At Fed That Long-run Neutral Rate Is Well Below Where Policy Rate Is Now; Last 6 Months Of PCE Inflation Is Very Close To 2%

PSNL

Personalis shares are trading higher after the company and Moderna recently announced a multi-year extension to continue utilizing the Personalis ImmunoID NeXT platform and technology for V940/mRNA-4157. The company also announced an investment from Merck.

On Friday, Galectin Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) released results from its global Phase2/3 NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42614531/galectin-therapeutics-announces-top-line-results-of-navigate-clinical-trial-evaluating-belapectin-" rel="noreferrer noopener">and portal hypertension</a>.
355 patients were randomized. The primary endpoint was defined as the prevention of varices (abnormally dilated blood vessels that can occur in the veins, arteries, or lymphatic vessels), assessed as a composite clinical outcome that included subjects with any varices, those with intercurrent events, or those without an endoscopy or intercurrent events at 18 months.
Intercurrent events were defined as any liver-related complication, treatment discontinuation due to adverse events, use of non-selective beta-blockers.
In the intent-to-treat population (N=355), while the incidence of varices was 43.2% reduced in the belapectin 2 mg/kg dose group vs placebo, the composite endpoint did not reach statistical significance.
The per-protocol population was pre-defined as subjects who completed 18 months of therapy with upper endoscopy performed at baseline and 18 months.
In the PPP (n=290), the incidence of varices was reduced by 48.9% (compared to the targeted 52.5% reduction) in the belapectin 2 mg/kg dose group.
Additionally, the company is conducting the full NAVIGATE trial data analysis. It anticipates having additional data from approximately 50 patients who have completed 36 months of treatment with belapectin in early 2025.
Once available, Galectin will provide clinical updates and determine the next steps for belapectin development.
Price Action: GALT stock is down 59% at $0.80 at last check Friday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42615125/why-is-bioengineered-human-tissue-focused-humacyte-stock-surging-on-friday" target="_blank" rel="noreferrer noopener">Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock.com

Biotech

Health Care

Movers

General

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

Oppenheimer analyst Brian Bittner reiterates Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Outperform and raises the price target from $182 to $200.

Reiteration

Oppenheimer Reiterates Outperform on Darden Restaurants, Raises Price Target to $200

Carnival Exec Says Expect 687 Dry Dock Days In 2025, An Increase Of 17% YoY

Feds Goolsbee Says Uncertainty On Policy Is Part Of Why I Feel Rate-Path Next Year Is A Bit More Shallow; Rates Will Go Come Down By A Judicious Amount Next Year

Oppenheimer analyst Bryan Blair reiterates Carlisle Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSL#NYSE">CSL</a>) with a Outperform and lowers the price target from $505 to $495.

Oppenheimer Reiterates Outperform on Carlisle Companies, Lowers Price Target to $495

Fed's Goolsbee Says 'Nice' To Get Inflation Number That's Better Than Expected; Still On Path To Get To 2% Inflation, Today's Data Shows Recent Firming Was A 'Bump'; There's More Uncertainty, Noise; My Projections Were For A Little More Shallow Rate-Path In 2025; Next 12-18 Months, Rates Can Go Down A Fair Amount; Employment Is Stable, Want To Keep It Stable, To Do So Rates Need To Come Down To Something Like Neutral; Agree Policy Rate Is Meaningful Restrictive

Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) is proving unstoppable, with shares soaring following <a href="https://www.benzinga.com/quote/PLTR/news">the announcement of</a> a significant U.S. Army contract extension on Thursday. 
This deal, which could reach $618.9 million over four years, underscores Palantir's growing role in delivering cutting-edge AI and data solutions for military operations.
Read More: <a href="https://www.benzinga.com//node/42572384">Palantir Strengthens Army Partnership, Adds AI And Data Enhancements In $618.9 Million Contract</a>
<h2 class="wp-block-heading">Palantir&#8217;s Winning Partnership With The Army</h2>
Since 2018, Palantir has been a cornerstone of the Army's Vantage program, empowering decision-making with advanced analytics and AI. 
The company's software integrates and visualizes data from multiple sources, enabling operational efficiencies and optimizing processes across the Army enterprise. 
With over 100,000 users, Vantage set a usage record this year, solidifying Palantir's reputation as a go-to tech partner.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20075533/Screenshot-2024-12-20-at-6.06.51-PM.png" alt="" class="wp-image-701635" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20075533/Screenshot-2024-12-20-at-6.06.51-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20075533/Screenshot-2024-12-20-at-6.06.51-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122024&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">Technical Tailwinds Could Push PLTR Stock Higher</h2>
From a technical standpoint, PLTR stock is in strong bullish territory:
<ul>
<li>Eight-day SMA: $73.58 (PLTR at $71.03 – selling pressure signals)</li>
<li>20-day SMA: $70.76 (bullish signal)</li>
<li>50-day SMA: $58.42 (bullish signal)</li>
<li>200-day SMA: $34.95 (bullish signal)</li>
</ul>
With a Relative Strength Index (RSI) of 56.46, the stock isn't overbought, suggesting room for further gains. The MACD of 4.23 reflects ongoing bullish momentum, adding weight to the upward trajectory.
<h2 class="wp-block-heading">What's Next For Palantir Stock?</h2>
As if the contract extension wasn&#8217;t enough, Palantir will join the Nasdaq 100 Index next Monday, a move expected to draw even more attention from institutional investors. Having already skyrocketed over 330% this year, PLTR stock is showing no signs of slowing down, cementing its status as one of the year's top-performing tech stocks.
With the U.S. Army deal and Nasdaq 100 inclusion, Palantir continues to defy gravity. Investors should prepare for what might be a transformative chapter in its growth journey.
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42608224/cathie-woods-thursday-moves-dumps-buzzing-stocks-tesla-and-palantir">Cathie Wood&#8217;s Thursday Moves: Dumps Buzzing Stocks Tesla And Palantir</a></li>
</ul>
Photo: Dennis Diatel/Shutterstock.com

Technicals

PLTR

Palantir Defies Gravity: Army Deal, Nasdaq 100 Spotlight Fuel Rally

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and maintains $25 price target.

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $120 price target.

CYTK

HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $120 Price Target

Macquarie analyst Tao Qiu maintains Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) with a Outperform and maintains $8 price target.

Macquarie Maintains Outperform on Brookdale Senior Living, Maintains $8 Price Target

Just one week after expanding its single-stock ETF suite, Direxion has launched new leveraged ETFs targeting two major players in the semiconductor industry: Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) <a href="https://www.benzinga.com/quote/MU/news">and Micron Technology Inc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>).



<h2 class="wp-block-heading">Broadcom And Micron – New Leveraged Bull &amp; Bear ETFs</h2>



With Thursday&#8217;s launch, active traders can magnify or inverse their exposure to Broadcom and Micron stocks using:



<ul>
<li>Direxion Daily AVGO Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVL#NASDAQ">AVL</a>)</li>



<li>Direxion Daily AVGO Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVS#NASDAQ">AVS</a>)</li>



<li>Direxion Daily MU Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MUU#NASDAQ">MUU</a>)</li>



<li>Direxion Daily MU Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MUD#NASDAQ">MUD</a>)</li>
</ul>



<h2 class="wp-block-heading">A Growing Suite Of Semiconductor ETFs</h2>



"Direxion is the leader in the semiconductor sector of the leveraged and inverse ETF universe, with over $13B in assets across the suite," said Edward Egilinsky, managing director at Direxion. "With the launch of the Broadcom and Micron Technologies ETFs, Direxion now has the largest suite of single-stock leveraged and inverse ETFs as well."



Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40652895/exclusive-beyond-the-magnificent-seven-direxions-egilinsky-reveals-top-sector-picks" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Beyond The Magnificent Seven — Direxion&#8217;s Egilinsky Reveals Top Sector Picks</a>



These ETFs offer traders new tools to tap into the price movements of Broadcom and Micron — both dominant names in the semiconductor space. Leveraged and inverse ETFs are designed for short-term trading, enabling traders to capitalize on market shifts without holding long-term positions.



<h2 class="wp-block-heading">Tools For High-Risk, Short-Term Traders</h2>



As always, Direxion advises that these ETFs are for experienced traders with a high risk tolerance. Leveraged products like these are not suitable for buy-and-hold strategies, as they seek to magnify short-term stock movements.



For traders, Direxion's new ETFs provide fresh opportunities to react to market volatility and industry trends — but it's crucial to stay vigilant, as the risks of trading with leverage are just as significant as the potential rewards.



Read Next: 



<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41163655/netflix-tsmc-traders-can-now-utilize-direxions-leveraged-etfs-for-bold-market-moves">Netflix, TSMC Traders Can Now Utilize Direxion&#8217;s Leveraged ETFs For Bold Market Moves</a></li>
</ul>



Photo: Shutterstock

Comments

Direxion Daily MU Bull 2X Shares

News

Latest news for Direxion Daily MU Bull 2X Shares (NASDAQ:MUU)

Thursday, October 10, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga